A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

NCT00774345 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

317

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Chronic Lymphocytic Leukemia

Interventions

DRUG: Lenalidomide
DRUG: Placebo

Sponsor

Celgene